SCHEMBL10187443

SCHEMBL10187443

CC(=O)Sc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.48
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
SRD5A2 P31213 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LTA4H P09960 3/20 0.47
NR1H2 P55055 1/20 0.47
BAX Q07812 1/20 0.47
TSHR P16473 1/20 0.46
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
EPHX1 P07099 1/20 0.45
PGR P06401 2/20 0.44
FFAR1 O14842 1/20 0.44
ACACB O00763 1/20 0.44
ACACA Q13085 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342299 0.81 CA12 (0.54) HPGDSMN1; SMN2ALDH1A1TSHRMAPT
SCHEMBL23709688 0.81 LTA4H (0.47) PARP10HPGDSMN1; SMN2SRD5A2ALDH1A1
SCHEMBL314336 0.80 SMN1; SMN2 (0.53) PARP10HPGDSMN1; SMN2SRD5A2ALDH1A1
Diphenylether SCHEMBL28412058 0.79 LTA4H (0.67) PARP10HPGDSMN1; SMN2SRD5A2LTA4H
Diphenylether SCHEMBL29175285 0.79 LTA4H (0.67) PARP10HPGDSMN1; SMN2SRD5A2LTA4H
Diphenylether SCHEMBL1830446 0.79 LTA4H (0.67) PARP10HPGDSMN1; SMN2SRD5A2LTA4H
SCHEMBL14341653 0.78 HPGD (0.46) HPGDALDH1A1MAPTRAB9ACA12
SCHEMBL5229538 0.78 MAPT (0.53) PARP10HPGDSMN1; SMN2ALDH1A1MAPT
SCHEMBL14367053 0.78 SMN1; SMN2 (0.54) HPGDSMN1; SMN2ALDH1A1TSHRMAPT
Diphenylether SCHEMBL8671677 0.77 LTA4H (0.63) PARP10HPGDSMN1; SMN2SRD5A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases MMP9, MMP1, MMP2 PARP10 2202/4885HPGD 189/4885SMN1; SMN2 2133/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 PARP10 1282/4885HPGD 98/4885SMN1; SMN2 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.